A U.S. Supreme Court ruling that, on the face of it, appears to jeopardize many biotech company patents is instead being welcomed in the industry, writes Daniela Hernandez. The ruling, to the effect that naturally occurring genes can’t be patented, now puts the focus on the key to competitive advantage, which derives not from the DNA itself but rather from how companies use that information.

Full Story:

Related Summaries